ALK and neoplasm: However, these drugs might be dissimilar in terms of the targeting profile, particularly against resistance mutations to previous TKIs and safety profiles, indicating that ALK-TKIs’ use may be influenced according to patients’ characteristics and the biological features of the tumor.